GlaxoSmithKline Executive’s Memo Suggested Burying Drug Studies

Glaxo Executive’s Memo Suggested Burying Drug Studies
An executive of GlaxoSmithKline Plc, the world’s second-biggest drugmaker, talked about burying negative studies linking its antidepressant drug Paxil to birth defects, according to a company memo introduced at a trial.
Read article at bloomberg.com